Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

To report the results of the DECT trial, a phase II study of locally advanced or operable HER2‐positive breast cancer (BC) treated with taxanes and concurrent anthracyclines and trastuzumab. Eligible patients (stage IIA‐IIIB HER2‐positive BC, 18–75 years, normal organ functions, ECOG ≤1, and left ve...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cell Physiol
Hlavní autoři: Pizzuti, Laura, Barba, Maddalena, Giannarelli, Diana, Sergi, Domenico, Botti, Claudio, Marchetti, Paolo, Anzà, Michele, Maugeri‐Saccà, Marcello, Natoli, Clara, Di Filippo, Simona, Catenaro, Teresa, Tomao, Federica, Amodio, Antonella, Carpano, Silvia, Perracchio, Letizia, Mottolese, Marcella, Di Lauro, Luigi, Sanguineti, Giuseppe, Di Benedetto, Anna, Giordano, Antonio, Vici, Patrizia
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089631/
https://ncbi.nlm.nih.gov/pubmed/27187274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.25432
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky